Intercytex is a regenerative medicine company developing
innovative products to restore skin and hair. Intercytex uses
its fully integrated cell technology platform to develop living,
human cell-based products that harness the innate ability of human
cells to regenerate and repair the body, at commercially viable
scale in attractive markets.
Intercytex commenced operations in 2000 and currently employs
around 80 staff. In addition to its head office in Cambridge,
UK, it has GMP compliant clinical production facilities plus
research and development laboratories in Manchester, UK. Additional
laboratories are located in Boston, USA.
Intercytex’ shares trade on the Alternative Investment
Market of the
London Stock Exchange under the ticker symbol ICX.L and on the
Open Market and the Xetra trading platform of the
Frankfurt Stock Exchange under the symbol IGJ.F.
Corporate fact sheet
|